Organisation paid for research Program year 2025 Source: CMS Open Payments

Multiple Doctors

Neither a doctor nor a teaching hospital

Research payments

$1,576,294

242 payments

Through program year 2025, Multiple Doctors is reported as receiving $1,576,294 in research payments, across 242 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$285,724	29
2024	Research	$151,581	14
2023	Research	$206,055	15
2022	Research	$233,663	56
2021	Research	$123,716	23
2020	Research	$169,454	29
2019	Research	$406,101	76

Breakdown

Who paid Research payments · program years 2019–2025

GlaxoSmithKline, LLC. $604,293 99 payments
Sanofi US Services Inc. $409,056 43 payments
E.R. Squibb & Sons, L.L.C. $294,636 31 payments
Celgene Corporation $91,698 17 payments
Novo Nordisk AS $85,454 38 payments
Janssen Research & Development, LLC $64,876 9 payments
Genzyme Corporation $24,979 3 payments
Sanofi-Aventis U.S. LLC $1,304 2 payments

Studies the money was for Research payments · program years 2019–2025

An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Stud $211,047 22 payments
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors $148,828 10 payments
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Evaluate T $125,404 4 payments
A Phase I/II, Randomized, Open-Label Platform Study Utilizing A Master $113,181 39 payments
Prospective REsearch Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE) $102,686 7 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $58,952 2 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $53,836 1 payment
Nn1250-4252 $52,718 5 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $51,595 4 payments
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para $37,152 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.